Connect your AI

Exagen Inc. XGN Purchase Obligation

Purchase Obligation at other companies

CTO

Citius Oncology, Inc.CTOR

$16.2M+260%

The RealRealREAL

$17.25M-1.8%

NuScale PowerSMR

$125.21M—

StereotaxisSTXS

$1.05M0.0%

HTF

Heartflow, Inc. Common StockHTFL

$250K—

Kulicke & Soffa IndustriesKLIC

$2.93M—

Other financials

Income statement

Revenue$17.3M+11.7%

Gross profit$10.2M+11.9%

Operating income-$3.4M-1.5%

Net income-$4.0M-5.7%

EPS (diluted)-$0.17+15.0%

Balance sheet

Cash & equivalents$21.7M+90.6%

Total debt$27.1M+15.8%

Total equity$14.4M+125%

Total assets$52.0M+28.9%

Cash flow

Operating cash flow-$10.4M+2.4%

CapEx$228.0K+102%

Free cash flow-$10.6M+1.3%

Valuation

Market cap$112.34M-26.5%

Enterprise value$117.78M-20.3%

P/S1.6×-1.0×

Profitability

Gross margin58.3%-1.0pp

Operating margin-20.6%-2.9pp

Net margin-29.5%+2.5pp

FCF margin-27.5%—

Returns & leverage

Return on equity-193.6%+355pp

Debt / equity1.9×-1.8×

Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:PurchaseObligation.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s purchase obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Exagen Inc.'s purchase obligation?: Exagen Inc. (XGN) reported purchase obligation of $24M in Q1 2026.